Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Doing a little jail time, not banned.
OT.....Free Hinchback...he is one of us, we need his post's here.TIA
MYSTERY MAN.....I know that's right!!!
BB Blue Chip...thanks
Correction(fuzzy math) 14,400,000,000 pills at .73 is $10,512,000,000 gross.
To treat 10 million people for a 4 year supply we would need 129,600,000,000 pills at .73 per pill would amount to $94,608,000,000. gross income. Let's get crankin'!!!
Not a problem.....eom
How huge is this??
NEW BRUNSWICK, NJ -- October 4, 2005 -- Xechem International, Inc. Xechem International announced today that its wholly owned subsidiary, Xechem UK Ltd., has received Orphan Drug designation from the European Medicine Evaluation Agency (EMEA) for Niprisan (now known as Nicosan(TM)/Hemoxin(TM)), a phytopharmaceutical product that has shown efficacy in the treatment of sickle cell disease.
The designation covers all 25 countries that comprise the European Union. Similar Orphan Drug status was previously granted to Xechem by the U.S. Food and Drug Administration.
Dr. Ramesh Pandey, Xechem's Chairman & CEO said, "Obtaining Orphan Drug status for our Sickle Cell Disease product in both the European Union and the United States brings to Xechem substantial advantages and incentives which will help facilitate approval of the drug and make it easier for us to bring this important medicine to market. To have received these coveted designations from both the FDA and EMEA for a natural, herb-based product such as ours is particularly gratifying."
Significance of Orphan Drug Designation
The EMEA regulation on orphan medicinal products is designed to encourage companies to develop and market treatments for rare, life threatening medical conditions that affect less than five people in every 10,000 in the EU. In addition to granting the license holder protection from direct or generic competition for a period of ten years within the EU following drug approval, orphan drug status allows for regulatory assistance, reduced regulatory fees associated with applying for marketing approval, protocol assistance and scientific advice. Similar incentives, including seven years of marketing exclusivity, tax credits, and access to potential grant funding for non-clinical and clinical research, accompany orphan drug status in the U.S.
According to Dr. Pandey, "Given the virtual lack of commercially viable treatments for SCD in the United States and the EU, the multi-year exclusivity for Nicosan(TM)/Hemoxin(TM) could create a significant revenue producing opportunity for Xechem."
About Sickle Cell Disease
Sickle Cell Disease (SCD) is a devastating hereditary blood disorder, caused by an abnormal Hemoglobin called Sickle Hemoglobin, and is characterized by acute painful crises, organ damage, anemia and early death. SCD is particularly prevalent among people from sub-Saharan Africa. In Nigeria alone over 4 million people are afflicted with the disease and another 26 million are believed to be carriers of the sickle cell trait. It is estimated that more than one out of seven persons living on the African continent carry the sickle cell trait and over 18 million actually suffer with the disease worldwide
Need more reminding of what we have here... .03 in a year is a joke, when this starts trading a penney at a time..look out!!!
Thursday, 6 July, 2006 will, definitely, remain indelible when history of technological achievement in Nigeria is documented. On that day, President Olusegun Obasanjo launched the Computer for All Initiative, (CANI) which will give more access to Nigerians to own computers in this age of information technology, and also commissioned the Gamma Irradiation Facility (GIF) as well as launched NICOSAN; a drug used for the management of sickle cell disorder. The last two projects have their respective plants at the Sheda Science and Technology Complex (SHESTCO), a parastatal under the Federal Ministry of Science and Technology. The Gamma Irradiation Facility is for the preservation, long shelf-life and judicious management of perishable foods and agricultural products while the NICOSAN is for the management of the sickle cell disease.
An important benefit of these recent developments is the economic undertones they have. These are in the areas of employment, economic empowerment, poverty eradication etc. Undoubtedly, the launch of the NICOSAN drug is a demonstration of Nigeria’s resolve to speak in the most pragmatic term at the international level. The launch of the drug and its acceptance in America where it has been granted the status of “orphan drug” is a testimony that something good can come out of Nigeria considering the past when Nigeria used to be the home of fake drugs.
It is a known fact that about 17 million people all over the world are suffering from this disease, and among these people are 4 million Nigerians. Therefore, the launch of NICOSAN will help these 17 million sickle cell patients in the world to manage the disease without any crisis as has been attested to by some of the patients who have been on the drug for over a year.
The launch of NICOSAN on Thursday, July 6, 2006 by President Obasanjo has changed the story of sickle cell patients. With NICOSAN, the history of the disease will turn around for the better, bringing with it a change in the dramatic and unpleasant experience which sufferers go through all their lives. As a potent management drug for the treatment of SCD, NICOSAN has been described by experts as the ‘defeat of sickle cell disease’. The knowledge and expertise of this drug are all indigenous which makes it a major breakthrough and a plus for the Ministry of Science and Technology.
President Obasanjo described the drug as a gift from Nigeria to the black race. Government in partnering with XECHEM, a private sector pharmaceutical company, will ensure that the NICOSAN drug is made available to all pharmaceutical stores in the next nine months. Meanwhile 30, 000 capsules have been produced in SHESTCO Abuja in XECHEM Laboratory to cater for the needs of those who are in need of the treatment, particularly those who have registered with XECHEM.
In the words of the Minister of Science and Technology, Professor Turner Isoun, “the story of NICOSAN is an interesting one. From an obscure practice by traditional herbal practitioners in the management of the disease, medical science has learnt only recently the potency of these extracts from different plants in use by our ancestors.” He went to state that patients on NICOSAN remain the most authentic testimony to its viability and efficacy in the management of the disease. Their continued living without crises since they began using the drug inspires great confidence. It should be noted that NICOSAN is the first drug to be developed out of indigenous knowledge and it has undergone rigorous laboratory research leading to patent award. It is also the first drug to be exported from Nigeria to other part of world. According to Dr. Ramesh Pandev, the Chairman of XECHEM, it is expected to earn the country about 150 million dollars per annum in foreign exchange earnings.
And one more.........
Virginia Commonwealth University researchers have developed a unique anti-sickling agent that may one day be effective in treating sickle cell disease, a painful and debilitating genetic blood disorder that affects approximately 80,000 Americans.
The research team led by Donald Abraham, Ph.D., the Alfred and Frances Burger Professor of Biological and Medicinal Chemistry, in the Department of Medicinal Chemistry in VCU's School of Pharmacy, has shown that 5-HMF, a pure compound developed by the team, has a high affinity for sickle cell hemoglobin and holds promise for the treatment of sickle cell disease.
"Our findings suggest that this anti-sickling agent may lead to new drug treatments and may one day help those suffering with sickle cell disease. This molecule, 5-HMF, is the most promising molecule to treat sickle cell anemia to come from our research group in more than 30 years," said Abraham, who is also the director of the Institute of Structural Biology and Drug Discovery.
The United States Patent and Trademark Office recently issued VCU a Notice of Allowance for a patent relating to a method of treating sickle cell disease with 5-HMF compound. A Notice of Allowance is a written notification that a patent application has cleared an internal review and it has been approved for issuance.
Sickle cell disease is caused by an abnormality in the hemoglobin molecule. Normal red blood cells carrying hemoglobin are smooth, round and flexible and can travel easily throughout blood vessels. However, sickle cells are stiff, abnormally shaped, red blood cells that do not flow freely through blood vessels. The sickle cells also may clot together causing a blockage to form which results in pain and potentially dangerous complications that can compromise a patient's organs.
According to Abraham, the 5-membered, heterocyclic, anti-sickling agent binds to hemoglobin to increase the oxygen affinity of both normal and sickle hemoglobin. In a patient with sickle cell disease, the binding action of 5-HMF would allow sickle cells to move more smoothly throughout the blood vessels of the body and prevent blockages from forming.
Abraham is internationally known for his groundbreaking work discovering and developing drugs that interact with hemoglobin. His research focus is to develop targeted therapeutics in sickle cell anemia, cardiovascular disease, stroke, cancer, Alzheimer's disease and radiation oncology.
This research was supported in part by a grant from the National Institutes of Health.
Xechem International, Inc., a biopharmaceutical company headquartered in New Brunswick, N.J., has entered into a licensing agreement with VCU Technology Transfer and has the exclusive worldwide rights for the production, sales and marketing of 5-HMF for use to fight sickle cell disease.
A recent grant from the National Heart, Lung and Blood Institute, part of the National Institutes of Health, awarded to Xechem International Inc., will allow researchers to carry out toxicity studies on 5-HMF. The research team will include researchers from VCU and Children's Hospital of Philadelphia, University of Philadelphia.
Working with Abraham to develop the anti-sickling agent were: Martin K. Safo, Ph.D., Richmond Danso-Danquah, Ph.D., and Gajanan S. Joshi, Ph.D., all researchers in the VCU Department of Medicinal Chemistry.
###
About Xechem: Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antimalarials, and antiviral (including AIDS), anticancer, antifungal and antibacterial products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem’s mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN™ (named HEMOXIN™ in the US and Europe) for the prophylactic management of Sickle Cell Disease (SCD). With the recent Nigerian regulatory approval of NICOSAN™, Xechem is now scaling-up the commercialization of the drug in Nigeria and making preparations for the pursuit of US FDA and European regulatory approval.
--------------------------------------------------------------------------------
About VCU and the VCU Medical Center:
Virginia Commonwealth University is the largest university in Virginia and ranks among the top 100 universities in the country in sponsored research. Located on two downtown campuses in Richmond, VCU enrolls more than 30,000 students in nearly 200 certificate and degree programs in the arts, sciences and humanities. Sixty-three of the programs are unique in Virginia, many of them crossing the disciplines of VCU’s 15 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation’s leading academic medical centers.For more, see www.vcu.edu.
Back to top
Another reminder.....
Nicosan
Nicosan (Hemoxin in US), previously Niprisan or Nix-0699, is a phytochemical (ethanol/water extract of Piper guineenses seeds, Pterocapus osum stem, Eugenia caryophyllum fruit, and Sorghum bicolor leaves) being tested for the treatment of Sickle-cell disease (SCD).
Development history
It was developed at the Nigerian National Institute for Pharmaceutical Research and Development (NIPRD) (U.S. Patent # 5,800,819 - September 1, 1998). NIPRD has already conducted Phase I, Phase IIa and IIb clinical trials and is currently conducting Phase III clinical trials in Nigeria.
In August 2002, Xechem International (XKEM/OTC:BB), a New Jersey company, acquired the exclusive world-wide rights to Niprisan (later re-named Nicosan/Hemoxin). On July 6, 2006 the drug was offically launched in Nigeria, with the President of Nigeria, Olusegun Obasanjo, personally in attendance.
The drug has begun with limited production, although it is expected that production will expand to meet demand.
Xechem International is currently in the process of preparing an Investigational New Drug (IND) Application for Nicosan/Hemoxin for submission to the United States Food and Drug Administration (FDA) and applicable EU agencies. Nicosan/Hemoxin has received orphan drug status in the USA and Europe.
Research findings
A Phase IIb trial of Nicosan was conducted at an army base hospital in Yaba, Lagos, Nigeria between 1996 and 1997. Xechem reports that ''"73% of the 30 patients who participated in the study experienced no crisis during the 12 month trial period and the remaining 27% experienced less frequent and less severecrises."'' - submission to U.S. Securities and Exchange Commission
A later study on 82 patients showed it significantly reduced the frequency of SCD crisis associated with severe pains.However the Cochrane Collaboration's review on phytochemicals for SCD also noted that this study showed that Nicosan "did not appear to affect the risk of severe complications or the level of anaemia".
The established drug hydroxyurea acts in SCD as an antisickling agent, however not all patients respond to this drug and some experience adverse effects, including myelosuppression. Nicosan with possibly less adverse effects also appears to work through "a strong antisickling effect" .
Footnotes
External links
* http://www.xechemnigeria.com Xechem Pharmaceuticals Nigeria homepage
Rate this Article
Was this article helpful?
Not at all Definitely
1 2 3 4 5
Sponsored Links
??????????
????????????????? ????,???????
www.jyslr.com
??????????
?????????,??????? ?????????????????
www.zhqiye.com
Email this page | Bookmark
Just a reminder.....
HOMEEyewitness NewsAccuweatherHealthSportsLife & StyleTroubleshooterResourcesInside ABC 11Jobs site web
Information in the press release below is distributed by companies featured through PR Newswire. Neither PR Newswire nor ABC can confirm the accuracy of the content.
Trade Policy Press Releases Press release distributed by PR Newswire
Ex-Im Bank Facility Supports Nigerian Pharmaceutical Production to Combat Sickle Cell Anemia
U.S. Companies Add Jobs to Fill Export Order
WASHINGTON, Oct. 31 /PRNewswire/ -- Companies in Florida, Georgia and
Illinois are exporting equipment and services to a Nigerian pharmaceutical
firm to help it in the fight against sickle cell anemia.
The exports by American Plastics Technologies, Inc., Schiller Park,
Ill.; FinancialBridge, Inc., Miami, Fla.; Nitra Group, Aventura, Fla.; and
Fisher Scientific Co. LLC, Suwanee, Ga., are being made possible by a $9.3
million loan guarantee from the Export-Import Bank of the United States
(Ex-Im Bank). American Plastics Technologies and FinancialBridge both are
small businesses.
Xechem Pharmaceuticals Nigeria Limited, Abuja, Nigeria will use the
funds to build laboratories and a manufacturing plant in Abuja to develop a
variety of herbal-based drugs to combat sickle cell anemia
Ex-Im Bank approved the medium-term loan guarantee under its new $300
million financing facility, allocated among 14 Nigerian banks, to support
U.S. exports to Nigeria. The consolidated facility is designed to expedite
the processing of short- and medium-term Ex-Im Bank financing for the
purchase of U.S. goods and services by Nigerian buyers. This is the third
transaction to be supported by the facility.
UPS Capital Business Credit of Hartford, Conn. is the guaranteed lender
on the transaction. Two Nigerian banks included in the facility, Diamond
Bank Ltd., and Access Bank Nigeria Plc., both of Lagos, are supporting the
transaction by providing co-guarantees.
"This transaction will support the development of Nigeria's
pharmaceutical infrastructure and at the same time create and sustain U.S.
jobs at small and large businesses alike," said Ex-Im Bank Chairman and
President James H. Lambright. "We look forward to the continued use of this
financing facility to make possible exports to Nigeria that otherwise would
not go forward, and to foster growth in Nigeria's banking sector and a wide
range of Nigerian industries."
"In the past, European businesses have aggressively used government
assisted financing to successfully compete against us, even though their
prices are 40-50 percent higher than ours," said American Plastics CEO Dr.
Rao K. Murukurthy. "Now with the help of Ex-Im Bank, we are reversing this
trend and selling internationally. This project to build a pharmaceutical
factory in Nigeria helps us to employ about 25 technicians and engineers
for about eight months. It also helps several of our U.S. vendors to employ
about 25 workers for six to eight months."
"Helping U.S. companies win global business is important to UPS Capital
and in this transaction, four U.S. companies, including two U.S. small
businesses, will be supported by the Export-Import Bank of the United
States," said Jim Fortsch, head of ECA Finance at UPS Capital. "Since the
funds provided by UPS Capital will be used to purchase plant equipment and
machinery for a state-of-the art pharmaceutical facility, this project is
especially rewarding."
Xechem, a wholly owned international subsidiary of Xechem
International, Inc., New Brunswick, N.J., is building the pharmaceutical
facilities under an agreement with Nigeria's National Institute for
Pharmaceutical Research and Development and Nigeria's Ministry of Health.
U.S. exporters interested in learning more about Ex-Im Bank's Nigerian
bank financing facility and how it can be used to support sales of U.S.
goods and services to Nigeria may contact the nearest Ex-Im Bank regional
office by calling 1-800-565-3946 and selecting option 2. Visit Ex-Im Bank's
web site at http://www.exim.gov.
Ex-Im Bank this year marks its 72nd year of helping finance the sale of
U.S. exports, primarily to emerging markets throughout the world. The Bank
works with commercial lenders to help U.S. companies increase export sales
and American jobs and minimize risk by accessing Ex-Im Bank financing and
export credit insurance.
OVER $800,000 In buying/selling/trading whatever,not earth shattering, but not chopped liver either, something is up!!! imo
MM's gotta be lovin this...IMO
Liquid...you selling?
Good morning all...
Picked up 1/2k .0219........eom
only 9.95......31.95 just to see green!!!
Picked up 1k @.022...........eom
Bid building..........eom
Free Hinchback...........eom
fox...nice boat!!!!!
I second that, my sentiments exactly..eom
OT Go Cowboys.........eom
Right on brother!!!! eom
Right on brother!!!! eom
Picked up 100k today @.0222..go XKEM!!!!
New MM ACAP??
Nice action now!!!eom
Are we thinking nicosan may be used for treating other diseases??
Post #67377 by stevo1981..pics
2 Seconds to late for the green close, gap up monday. IMO
Good day guys and gals, close at HOD.. Happy Thanksgiving everybody and drive safe!
Yes, I'm in for a donation!!eom
A guy I work with has to wait for money to clear(3-4 days) before he can buy otc, but I don't, we haven't figured it out yet except I have a margin acct. Who the heck knows?
I've been buying XKEM steady online for the last 60 days thru tdameritrade. no BS...9/25 till present, there were a few days in there where they restricted, but no more than a week.
maybe I can get them to waive the fee....hehehe
Sorry all done here down to $6.82.eom
their done!!
I put a buy in at 1000 @ .021 filled @ .0209